EDGAR·FLOW

SCYNEXIS INC — Form 8-K

Filed September 28, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
SCYNEXIS received a contract from BARDA (U.S. Department of Health and Human Services) providing up to $214 million in non-dilutive funding to develop SCY-247, a second-generation antifungal candidate, through NDA submission for two indications (treatment of invasive candidiasis and prevention of invasive fungal infections). The initial base period provides $18.5 million; the contract is structured as a cost-share arrangement and may extend up to 10 years. The company maintains its existing cash runway guidance into 2029 and states SCY-770 (lead ADPKD program) development milestones remain unchanged.
Why this rating

Contract value ($214M potential, $18.5M immediate) is 8.3× company market cap—transformational for a $25.7M company. Non-dilutive funding eliminates dilution, extends runway, enables pipeline expansion. However, contingent on option exercise and cost-share obligations; does not alter lead program trajectory.

Tradability signal
NO TRADE

No trade: positive news with only -3.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.36% over 4 hrs, n=137). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$4.71 ▲ 2.04%
at our read · unknown
$4.62
+10 min · unknown
$4.62 ▼ 0.11%
+30 min · unknown
$4.63 ▲ 0.22%
+1 hr · unknown
$4.57 ▼ 1.08%
+4 hrs · unknown
$4.65 ▲ 0.65%

The stock had already moved -2.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SCYX · stock on Yahoo Finance ↗

See more from September 28, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.